DE3856440T2 - Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendungen - Google Patents
Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren AnwendungenInfo
- Publication number
- DE3856440T2 DE3856440T2 DE3856440T DE3856440T DE3856440T2 DE 3856440 T2 DE3856440 T2 DE 3856440T2 DE 3856440 T DE3856440 T DE 3856440T DE 3856440 T DE3856440 T DE 3856440T DE 3856440 T2 DE3856440 T2 DE 3856440T2
- Authority
- DE
- Germany
- Prior art keywords
- applications
- antibodies produced
- antibody genes
- modular assembly
- region modules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7752887A | 1987-07-24 | 1987-07-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3856440D1 DE3856440D1 (de) | 2000-12-07 |
DE3856440T2 true DE3856440T2 (de) | 2001-06-13 |
Family
ID=22138605
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3856440T Ceased DE3856440T2 (de) | 1987-07-24 | 1988-07-25 | Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendungen |
DE200812000039 Pending DE122008000039I1 (de) | 1987-07-24 | 1988-07-25 | Modularer Zusammenbau von Antikorpergenen, dadurchhergestellte Antikorper und deren Anwendungen. |
DE3855421T Expired - Lifetime DE3855421T2 (de) | 1987-07-24 | 1988-07-25 | Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendung |
DE3888186T Expired - Lifetime DE3888186T3 (de) | 1987-07-24 | 1988-07-25 | Modulärer zusammenbau von antikörpergenen, dadurch hergestellte antikörper und deren anwendung. |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200812000039 Pending DE122008000039I1 (de) | 1987-07-24 | 1988-07-25 | Modularer Zusammenbau von Antikorpergenen, dadurchhergestellte Antikorper und deren Anwendungen. |
DE3855421T Expired - Lifetime DE3855421T2 (de) | 1987-07-24 | 1988-07-25 | Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendung |
DE3888186T Expired - Lifetime DE3888186T3 (de) | 1987-07-24 | 1988-07-25 | Modulärer zusammenbau von antikörpergenen, dadurch hergestellte antikörper und deren anwendung. |
Country Status (8)
Country | Link |
---|---|
EP (3) | EP0550400B1 (de) |
JP (1) | JP2991720B2 (de) |
AT (2) | ATE140266T1 (de) |
AU (1) | AU632462B2 (de) |
CA (1) | CA1341235C (de) |
DE (4) | DE3856440T2 (de) |
DK (1) | DK174824B1 (de) |
WO (1) | WO1989000999A1 (de) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
DE3744595A1 (de) * | 1987-12-31 | 1989-07-13 | Andreas Dr Plueckthun | Verfahren zur gentechnischen herstellung von antikoerpern |
GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
JP2980626B2 (ja) * | 1988-01-11 | 1999-11-22 | ゾーマ・コーポレーション | ペクチン酸リアーゼのシグナル配列を含む新規プラスミドベクター |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US6291160B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6680192B1 (en) | 1989-05-16 | 2004-01-20 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6969586B1 (en) | 1989-05-16 | 2005-11-29 | Scripps Research Institute | Method for tapping the immunological repertoire |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
JP4157160B2 (ja) * | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
JP2002514919A (ja) * | 1997-04-04 | 2002-05-21 | バイオサイト ダイアグノスティックス,インコーポレイテッド | 多価ライブラリーおよびポリクローナルライブラリー |
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
US7250494B2 (en) | 1998-06-15 | 2007-07-31 | Biosynexus Incorporated | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
EA004107B1 (ru) | 1998-08-11 | 2003-12-25 | Айдек Фармацевтикалс Корпорэйшн | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 |
WO2000027428A1 (en) | 1998-11-09 | 2000-05-18 | Idec Pharmaceuticals Corporation | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
EP1259548A1 (de) | 2000-02-24 | 2002-11-27 | Eidgenössische Technische Hochschule Zürich | Antikörper gegen die ed-b domäne von fibronektin, konjugate die diesen antikörper enthalten, und deren verwendung zum nachweis und zur behandlung von angiogenese |
EP1749889A1 (de) * | 2000-06-05 | 2007-02-07 | Corixa Corporation | Leader-Anteile zur Erhöhung der Sekretion von rekombinanten Proteinen aus einer Wirtzelle |
ATE321870T1 (de) * | 2000-06-05 | 2006-04-15 | Corixa Corp | Leader-anteile zur erhöhung der sekretion von rekombinanten proteine aus einer wirtzelle |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
AU2001297872B2 (en) | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
WO2002061090A2 (en) * | 2000-12-14 | 2002-08-08 | Genentech, Inc. | Prokaryotically produced antibodies and uses thereof |
RU2287574C2 (ru) | 2000-12-14 | 2006-11-20 | Дженентек, Инк. | БАКТЕРИЯ Е.coli, ПРОДУЦИРУЮЩАЯ ГЕТЕРОЛОГИЧНЫЙ ПОЛИПЕПТИД, И СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
EP1414471B1 (de) | 2001-07-17 | 2012-06-13 | Research Development Foundation | Therapeutische Mittel mit pro-apoptotischen Proteinen |
MXPA04001566A (es) | 2001-08-27 | 2004-05-17 | Genentech Inc | Un sistema para expresion y ensamblado de anticuerpos. |
US20040052779A1 (en) * | 2001-12-21 | 2004-03-18 | Stinson Jeffrey R. | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
EP1903115B1 (de) | 2006-09-22 | 2011-03-09 | Wacker Chemie AG | Verfahren zur fermentativen Herstellung von Antikörpern |
KR101280704B1 (ko) * | 2007-10-12 | 2013-07-01 | 에프. 호프만-라 로슈 아게 | 다수의 핵산으로부터의 단백질 발현 |
KR20110031343A (ko) | 2008-06-20 | 2011-03-25 | 와이어쓰 엘엘씨 | 베타-용혈성 스트렙토코커스 균주로부터 유래된 orf1358을 사용하는 조성물 및 방법 |
KR20160116056A (ko) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-il-12/il-23 항체 |
CN102459591B (zh) | 2009-05-20 | 2015-05-13 | 诺维莫尼公司 | 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法 |
EP2990485B1 (de) | 2013-04-25 | 2019-09-11 | Kaneka Corporation | Fd-kettengen oder l-kettengen zur erhöhung der sekretionsmenge des antikörpers vom fab-typ |
HRP20220748T1 (hr) | 2013-12-24 | 2022-09-02 | Janssen Pharmaceutica Nv | Anti-vista antitijela i fragmenti |
KR101921552B1 (ko) | 2014-03-10 | 2018-11-23 | 리히터 게데온 닐트. | 사전 세정 단계를 이용하는 면역글로불린 정제 |
DK3313882T3 (da) | 2015-06-24 | 2020-05-11 | Janssen Pharmaceutica Nv | Anti-VISTA antistoffer og fragmenter |
US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
US10765724B2 (en) | 2016-03-29 | 2020-09-08 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
CA3037961A1 (en) | 2016-09-30 | 2018-04-05 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il23 specific antibody |
JP2020502261A (ja) | 2016-11-16 | 2020-01-23 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体で乾癬を治療する方法 |
KR20240038146A (ko) | 2017-01-30 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
CN110418652A (zh) | 2017-02-07 | 2019-11-05 | 詹森生物科技公司 | 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法 |
WO2018162517A1 (en) | 2017-03-10 | 2018-09-13 | F. Hoffmann-La Roche Ag | Method for producing multispecific antibodies |
TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
CA3092551A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
DK3883606T5 (da) | 2018-09-24 | 2024-01-02 | Janssen Biotech Inc | Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof |
KR20210093973A (ko) | 2018-11-20 | 2021-07-28 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법 |
WO2020128864A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
MX2021008537A (es) | 2019-01-15 | 2021-11-12 | Janssen Biotech Inc | Composiciones de anticuerpos anti-tnf y métodos para el tratamiento de la artritis idiopática juvenil. |
KR20210118878A (ko) | 2019-01-23 | 2021-10-01 | 얀센 바이오테크 인코포레이티드 | 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물 |
US20220153829A1 (en) | 2019-03-14 | 2022-05-19 | Janssen Biotech, Inc. | Methods for Producing Anti-TNF Antibody Compositions |
EP3938384A4 (de) | 2019-03-14 | 2022-12-28 | Janssen Biotech, Inc. | Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen |
JP2022526881A (ja) | 2019-03-14 | 2022-05-27 | ヤンセン バイオテツク,インコーポレーテツド | 抗tnf抗体組成物を産生するための方法 |
MA55282A (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | Procédés de fabrication pour la production de compositions d'anticorps anti-tnf |
BR112021018441A2 (pt) | 2019-03-18 | 2023-02-28 | Janssen Biotech Inc | Método para tratamento de psoríase em indivíduos pediátricos com anticorpo anti-il12/il23 |
MX2021014302A (es) | 2019-05-23 | 2022-01-04 | Janssen Biotech Inc | Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa. |
CA3142580A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
WO2020245676A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
EP4305062A1 (de) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Verfahren zur behandlung von patienten mit psoriasisarthritis mit unzureichender reaktion auf eine tnf-therapie mit anti-il23-spezifischem antikörper |
US20220298236A1 (en) | 2021-03-12 | 2022-09-22 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody |
AU2022306144A1 (en) | 2021-07-09 | 2024-02-22 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
IL309996A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Production methods for the production of anti-TNF antibody compositions |
CN117916260A (zh) | 2021-07-09 | 2024-04-19 | 詹森生物科技公司 | 用于制备抗il12/il23抗体组合物的制造方法 |
KR20240099352A (ko) | 2021-10-29 | 2024-06-28 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 크론병을 치료하는 방법 |
AU2022388887A1 (en) | 2021-11-15 | 2024-07-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2024110898A1 (en) | 2022-11-22 | 2024-05-30 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS59187782A (ja) * | 1983-04-09 | 1984-10-24 | Kyowa Hakko Kogyo Co Ltd | 免疫グロブリンをコ−ドする新規dna |
JPS6147500A (ja) * | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (de) * | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) * | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
EP0247091B1 (de) * | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung |
IL84285A (en) * | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
JP2980626B2 (ja) * | 1988-01-11 | 1999-11-22 | ゾーマ・コーポレーション | ペクチン酸リアーゼのシグナル配列を含む新規プラスミドベクター |
-
1988
- 1988-07-20 CA CA000572398A patent/CA1341235C/en not_active Expired - Lifetime
- 1988-07-25 DE DE3856440T patent/DE3856440T2/de not_active Ceased
- 1988-07-25 DE DE200812000039 patent/DE122008000039I1/de active Pending
- 1988-07-25 AT AT93100041T patent/ATE140266T1/de not_active IP Right Cessation
- 1988-07-25 AU AU23244/88A patent/AU632462B2/en not_active Expired
- 1988-07-25 EP EP93100041A patent/EP0550400B1/de not_active Expired - Lifetime
- 1988-07-25 JP JP63506481A patent/JP2991720B2/ja not_active Expired - Lifetime
- 1988-07-25 AT AT95119798T patent/ATE197315T1/de not_active IP Right Cessation
- 1988-07-25 DE DE3855421T patent/DE3855421T2/de not_active Expired - Lifetime
- 1988-07-25 WO PCT/US1988/002514 patent/WO1989000999A1/en active IP Right Grant
- 1988-07-25 EP EP88907510A patent/EP0371998B2/de not_active Expired - Lifetime
- 1988-07-25 EP EP95119798A patent/EP0731167B1/de not_active Expired - Lifetime
- 1988-07-25 DE DE3888186T patent/DE3888186T3/de not_active Expired - Lifetime
-
1990
- 1990-01-24 DK DK199000192A patent/DK174824B1/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE197315T1 (de) | 2000-11-15 |
EP0550400A2 (de) | 1993-07-07 |
DK19290D0 (da) | 1990-01-24 |
EP0371998A4 (en) | 1991-11-21 |
AU632462B2 (en) | 1993-01-07 |
JP2991720B2 (ja) | 1999-12-20 |
DE122008000039I1 (de) | 2011-12-01 |
EP0731167A1 (de) | 1996-09-11 |
DK174824B1 (da) | 2003-12-08 |
DE3856440D1 (de) | 2000-12-07 |
WO1989000999A1 (en) | 1989-02-09 |
CA1341235C (en) | 2001-05-22 |
EP0550400B1 (de) | 1996-07-10 |
AU2324488A (en) | 1989-03-01 |
EP0731167B1 (de) | 2000-11-02 |
DE3855421D1 (de) | 1996-08-14 |
DE3855421T2 (de) | 1997-03-06 |
EP0550400A3 (en) | 1993-10-06 |
EP0371998A1 (de) | 1990-06-13 |
DK19290A (da) | 1990-03-23 |
DE3888186D1 (de) | 1994-04-07 |
DE3888186T2 (de) | 1994-09-22 |
JPH03501321A (ja) | 1991-03-28 |
EP0371998B2 (de) | 1999-11-03 |
ATE140266T1 (de) | 1996-07-15 |
DE3888186T3 (de) | 2000-08-24 |
EP0371998B1 (de) | 1994-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3856440D1 (de) | Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendungen | |
DE69329877T2 (de) | Von L Protein abgeleitete Immunoglobulin-bindende Proteine und deren anwendungen | |
KR920000789A (ko) | 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 용도 | |
ATE286126T1 (de) | Glialmitogene faktoren, ihre herstellung und verwendung | |
ATE414150T1 (de) | Einzelkettiges, mehrfach-antigenbindendes molekül,dessen herstellung und verwendung | |
DE3864585D1 (de) | Dns-molekule, codierend fuer non-a-non-b-hepatitis-antigene und ihre verwendung zur herstellung dieser antigene. | |
DE58909458D1 (de) | Antigenkonstrukte von "Major Histocompatibility Complex" Klasse I Antigenen mit spezifischen Trägermolekülen, ihre Herstellung und Verwendung. | |
DE69839444D1 (de) | Smad 6 und dessen anwendungen | |
DE69021263D1 (de) | Fibronektinbindungsprotein und dessen Herstellung. | |
DE69034261D1 (de) | Antikörper gegen VLA-4 | |
SE9201331D0 (sv) | Protein l och hybridproteiner daerav | |
ATE227343T1 (de) | Protease und verwandte dns-verbindungen | |
DE59010418D1 (de) | Monoklonale Antikörper (MAK) gegen tumorassoziierte Antigene, ihre Herstellung und Verwendung | |
DE68918217D1 (de) | Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs. | |
DE3853446D1 (de) | Fibronectinbindungsprotein und dessen Herstellung. | |
EP0340391A3 (en) | 1,4-disubstituted-2,3,4,6-tetrahydroxy-1,4-diphosphorinane and their oxides or sulfides | |
ATE229069T1 (de) | Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren | |
DE68909515D1 (de) | Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen. | |
DE3876114D1 (de) | Benzodioxol-derivate, diese enthaltende zusammensetzungen und deren verwendung zur herstellung von medikamenten. | |
PT86891A (pt) | Tendamistat-derivate | |
ATE247980T1 (de) | Verwendung von an glycoprotein gpiib/iiia bindenden substanzen zur vermeidung von stenosis und restenosis | |
KR950018051A (ko) | 싸이모신-알파와 다른 싸이토킨이 융합된 융합 단백질 | |
ATE102249T1 (de) | Modulaerer zusammenbau von antikoerpergenen, dadurch hergestellte antikoerper und deren anwendung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPC2 | Refusal decision in registration proceedings for a supplementary protection certificate (spc) | ||
R003 | Refusal decision now final |
Free format text: PRODUCT NAME: CERTOLIZUMAB PEGOL, (ARZNEIMITTEL CIMZIA) INCL. ALLE VERSCHIEDENEN FORMEN UND POST-TRA: 57856 20070907 NSLATIONEN MODIFIKATIONEN VON CERTOLUZIMAB PEGOL, SOWIE SALZE UND ESTER DAVON.; REGISTRATION NO/DATE Spc suppl protection certif: 122008000039 Filing date: 20080723 Expiry date: 20080726 |